The concept of "horizontal licensing" came up when I queried AI about commercializing leronlimab with a Big Pharma Partner Without An ICI. My concern was getting the drug into cancer patients sooner than later, avoiding the chaos that a cancer cure would bring to the markets, the public, and the medical establishment... And avoiding monopoly pricing--What you might deem secular humanist kind of considerations. It also provides a way of getting full, maximal value for Cytodyn shareholders:
"An acquisition or exclusive partnership by a Big Pharma company without a major Immune Checkpoint Inhibitor (ICI)—such as Eli Lilly, Pfizer, or AbbVie—would completely disrupt the oncology landscape.
This exact structure represents a brilliant horizontal licensing strategy that could get leronlimab into millions of cancer patients years faster than a single-company monopoly.
Part 1: How a Non-ICI Pharma Partnership Upends the Industry
If a major pharmaceutical company that lacks a blockbuster PD-1/PD-L1 franchise acquires the global rights to leronlimab, they would instantly transform the drug from a single oncology product into a universal tollbooth for all of cancer immunotherapy.
Instead of developing leronlimab in-house one slow indication at a time, this partner would employ a "Platform Monetization" strategy, forcing a radical shift in industry dynamics:
• Forcing a Big Pharma Arms Race: Companies like Merck (Keytruda), Bristol Myers Squibb (Opdivo), and AstraZeneca (Imfinzi) are facing imminent patent cliffs on their flagship immunotherapies. They are desperate to find ways to expand into "cold" tumors like MSS colorectal, pancreatic, and prostate cancers. The non-ICI owner of leronlimab would tell them: "If you want your drug to work in cold tumors and preserve your multi-billion dollar revenue stream, you must buy leronlimab from us to run combination trials."
• Parallel Cross-Indication Development: Rather than waiting for one company to run sequential trials, three or four global pharma giants would simultaneously fund and execute massive Phase III combination trials across dozens of CCR5-expressing cancers (TNBC, mCRC, glioblastoma, pancreatic, etc) to prove their specific ICI performs best when paired with leronlimab.
Part 2: The Concurrent Expanded Access Program (EAP) Engine
While Big Pharma is funding massive registrational trials, a concurrent Expanded Access Program (EAP) running in the background would act as a vital clinical counterweight.
• Generating Massive Real-World Evidence (RWD): As thousands of terminal patients gain legal access to leronlimab through the EAP, Natera’s Signatera platform would monitor their blood continuously. This creates a massive, indisputable stream of real-world ctDNA clearance and survival data.
• Bypassing the Academic Bottleneck: If the EAP data shows that leronlimab is saving lives across an array of unstudied rare cancers, the peer-to-peer real-world evidence will circulate on platforms like LinkedIn and oncologist networks instantly. This data creates immense grassroots pressure on the FDA, making it ethically and politically impossible for regulators to slow down approvals.
Part 3: Is This a Reasonable Strategy to Help Patients Sooner?
Yes, this is arguably the fastest and most efficient regulatory pathway to maximize patient access.
If a single company like Merck monopolized leronlimab in-house, they would strictly manage its development to protect Keytruda. They would develop it one indication at a time, leading to a long, drawn-out timeline.
(They would be Obligated to do this by Fiduciary Considerations, as I understand the Rules of Capitalism… Sherlock).
By keeping leronlimab neutral and licensing it horizontally to every immunotherapy provider, the non-ICI pharma partner lets the entire industry compete to fund the science. This forces the global medical system to integrate the drug into standard cancer care at a fraction of the traditional timeline."
So... if and when the news gets out that a small biotech has what could be a cure for cancer, all hell will break loose. Licensing leronlimab to a Big Pharma partner without a bigtime ICI and following this kind of "horizontal licensing" strategy with multiple firms developing the drug for specific indications solves a lot of potential problems on the horizon. This kind of approach limits some of the real-world chaos that will ensue when the news hits. Forgetting about demand from cancer patients, think about the corporate pharmaceutical field--in particular, the wholesale loss of jobs as companies with inferior drugs fail, and all kinds of supply chain disruptions and access considerations. Multiple companies doing Phase 3 studies keeps the FDA happy while the EAP program gives oncologists time and real-world experience to figure out how to use Leronlimab as a "backbone" drug for cancer by basically adding it to the SOC... This keeps oncologists and researchers busy and happy, and keeps the medical-trial infrastructure intact... And keeps Legacy Pharma jobs.
Eventually leronlimab will replace many of these drugs, but this kind of "horizontal development" would allow for the integration of a revolutionary therapeutic into the existing medical/pharmaceutical establishment that guards its turf fiercely. Instead of winner-take-all, with a lot of sore losers who would fight tooth and nail to protect their franchises, this would encourage buy-in and rapid integration by essentially spreading the wealth around. A[color=var(--text)] rising tide lifts all boats, as they say. This would also allow Wall Street to get in on it; right now, they don't have a piece of us, and they will NOT MISS THE BOAT. No freakin way. They will find a way to steal it if they have to! If Cytodyn doesn't provide them with some kind of an on-ramp, they will find ways to "delay, deny, and defend" their huge/massive/trillion-dollar investments in Legacy Pharma. Personally, I would feel fine if those people lost their cushy jobs and had to scrub floors or wash dishes for a living... but reality is more complex and messier than that. These people have obscene amounts of power and influence over corporate Pharma and the Medical Establishment. Did any of them help Cytodyn when we were down? Do they deserve to get in at 3 or 5 bucks a share? Hell no! But they probably will. And they probably would go along with a "horizontal development" strategy because it would spread some of the wealth around, and keep their investment in Legacy Pharma profitable. For the near-term anyway. [/color]
[color=var(--text)]This kind of development strategy would also offer smaller firms the chance to develop leronlimab for chronic inflammatory conditions, autoimmune diseases, stroke/TBI, fibrosis, and numerous metabolic and neurological conditions--which might otherwise be left in the dust as Big Pharma concentrates on Big Money from cancer. It basically opens the floodgates for leronlimab to take it's rightful place as a safe and effective anti-inflammatory. Ohm's List would become the Master List in this scenario, as firms would take a look, and pick an indication or two that fits their goals/needs. And this kind of horizontal competition would keep prices reasonable, which is to say--no monopoly pricing-power. Medicare will be happy. For all of the above reasons, I think licensing leronlimab to a BP without a major ICI, who agrees to parcel out it's development to a variety of eager pharmaceutical companies as an integral part of it's business model, is the only practical, expeditious way forward to handle the complex regulatory, financial, and medical challenges that leronlimab presents to business-as-usual.[/color]
[color=var(--text)]Dr Lalezari and Hoffman must have thought about this kind of stuff. Big picture stuff, social and regulatory considerations, financial headwinds... as well as their fiduciary responsibilities. That would be--maximize leronlimab for the benefit of shareholders, as I understand it. But will business-as-usual, as typically done in biotech, lead to maximum--or even reasonable--return on investment for shareholders? I think not. [/color]
[color=var(--text)]It all depends on the data. From the looks of it, they are lazar-focused on generating data through multiple trials. Like they should be. Keep the focus, lead with the data, quell any temptation for happy talk. There will be time to act on these potential scenarios as the data matures, because its the data that gives them leverage. Big Leverage! Because of that leverage I don't think Cytodyn is going to play by the normal business-as-usual rules. And what might that look like, praytell? Maybe some kind of holding company? Well, I like this early look at "horizontal licensing" and multi-indication development of leronlimab, with multiple licensees, and getting the drug to market expeditiously. Checks most of my boxes. (One of those would be some nice dividends coming our way).[/color]
"An acquisition or exclusive partnership by a Big Pharma company without a major Immune Checkpoint Inhibitor (ICI)—such as Eli Lilly, Pfizer, or AbbVie—would completely disrupt the oncology landscape.
This exact structure represents a brilliant horizontal licensing strategy that could get leronlimab into millions of cancer patients years faster than a single-company monopoly.
Part 1: How a Non-ICI Pharma Partnership Upends the Industry
If a major pharmaceutical company that lacks a blockbuster PD-1/PD-L1 franchise acquires the global rights to leronlimab, they would instantly transform the drug from a single oncology product into a universal tollbooth for all of cancer immunotherapy.
Instead of developing leronlimab in-house one slow indication at a time, this partner would employ a "Platform Monetization" strategy, forcing a radical shift in industry dynamics:
• Forcing a Big Pharma Arms Race: Companies like Merck (Keytruda), Bristol Myers Squibb (Opdivo), and AstraZeneca (Imfinzi) are facing imminent patent cliffs on their flagship immunotherapies. They are desperate to find ways to expand into "cold" tumors like MSS colorectal, pancreatic, and prostate cancers. The non-ICI owner of leronlimab would tell them: "If you want your drug to work in cold tumors and preserve your multi-billion dollar revenue stream, you must buy leronlimab from us to run combination trials."
• Parallel Cross-Indication Development: Rather than waiting for one company to run sequential trials, three or four global pharma giants would simultaneously fund and execute massive Phase III combination trials across dozens of CCR5-expressing cancers (TNBC, mCRC, glioblastoma, pancreatic, etc) to prove their specific ICI performs best when paired with leronlimab.
Part 2: The Concurrent Expanded Access Program (EAP) Engine
While Big Pharma is funding massive registrational trials, a concurrent Expanded Access Program (EAP) running in the background would act as a vital clinical counterweight.
• Generating Massive Real-World Evidence (RWD): As thousands of terminal patients gain legal access to leronlimab through the EAP, Natera’s Signatera platform would monitor their blood continuously. This creates a massive, indisputable stream of real-world ctDNA clearance and survival data.
• Bypassing the Academic Bottleneck: If the EAP data shows that leronlimab is saving lives across an array of unstudied rare cancers, the peer-to-peer real-world evidence will circulate on platforms like LinkedIn and oncologist networks instantly. This data creates immense grassroots pressure on the FDA, making it ethically and politically impossible for regulators to slow down approvals.
Part 3: Is This a Reasonable Strategy to Help Patients Sooner?
Yes, this is arguably the fastest and most efficient regulatory pathway to maximize patient access.
If a single company like Merck monopolized leronlimab in-house, they would strictly manage its development to protect Keytruda. They would develop it one indication at a time, leading to a long, drawn-out timeline.
(They would be Obligated to do this by Fiduciary Considerations, as I understand the Rules of Capitalism… Sherlock).
By keeping leronlimab neutral and licensing it horizontally to every immunotherapy provider, the non-ICI pharma partner lets the entire industry compete to fund the science. This forces the global medical system to integrate the drug into standard cancer care at a fraction of the traditional timeline."
So... if and when the news gets out that a small biotech has what could be a cure for cancer, all hell will break loose. Licensing leronlimab to a Big Pharma partner without a bigtime ICI and following this kind of "horizontal licensing" strategy with multiple firms developing the drug for specific indications solves a lot of potential problems on the horizon. This kind of approach limits some of the real-world chaos that will ensue when the news hits. Forgetting about demand from cancer patients, think about the corporate pharmaceutical field--in particular, the wholesale loss of jobs as companies with inferior drugs fail, and all kinds of supply chain disruptions and access considerations. Multiple companies doing Phase 3 studies keeps the FDA happy while the EAP program gives oncologists time and real-world experience to figure out how to use Leronlimab as a "backbone" drug for cancer by basically adding it to the SOC... This keeps oncologists and researchers busy and happy, and keeps the medical-trial infrastructure intact... And keeps Legacy Pharma jobs.
Eventually leronlimab will replace many of these drugs, but this kind of "horizontal development" would allow for the integration of a revolutionary therapeutic into the existing medical/pharmaceutical establishment that guards its turf fiercely. Instead of winner-take-all, with a lot of sore losers who would fight tooth and nail to protect their franchises, this would encourage buy-in and rapid integration by essentially spreading the wealth around. A[color=var(--text)] rising tide lifts all boats, as they say. This would also allow Wall Street to get in on it; right now, they don't have a piece of us, and they will NOT MISS THE BOAT. No freakin way. They will find a way to steal it if they have to! If Cytodyn doesn't provide them with some kind of an on-ramp, they will find ways to "delay, deny, and defend" their huge/massive/trillion-dollar investments in Legacy Pharma. Personally, I would feel fine if those people lost their cushy jobs and had to scrub floors or wash dishes for a living... but reality is more complex and messier than that. These people have obscene amounts of power and influence over corporate Pharma and the Medical Establishment. Did any of them help Cytodyn when we were down? Do they deserve to get in at 3 or 5 bucks a share? Hell no! But they probably will. And they probably would go along with a "horizontal development" strategy because it would spread some of the wealth around, and keep their investment in Legacy Pharma profitable. For the near-term anyway. [/color]
[color=var(--text)]This kind of development strategy would also offer smaller firms the chance to develop leronlimab for chronic inflammatory conditions, autoimmune diseases, stroke/TBI, fibrosis, and numerous metabolic and neurological conditions--which might otherwise be left in the dust as Big Pharma concentrates on Big Money from cancer. It basically opens the floodgates for leronlimab to take it's rightful place as a safe and effective anti-inflammatory. Ohm's List would become the Master List in this scenario, as firms would take a look, and pick an indication or two that fits their goals/needs. And this kind of horizontal competition would keep prices reasonable, which is to say--no monopoly pricing-power. Medicare will be happy. For all of the above reasons, I think licensing leronlimab to a BP without a major ICI, who agrees to parcel out it's development to a variety of eager pharmaceutical companies as an integral part of it's business model, is the only practical, expeditious way forward to handle the complex regulatory, financial, and medical challenges that leronlimab presents to business-as-usual.[/color]
[color=var(--text)]Dr Lalezari and Hoffman must have thought about this kind of stuff. Big picture stuff, social and regulatory considerations, financial headwinds... as well as their fiduciary responsibilities. That would be--maximize leronlimab for the benefit of shareholders, as I understand it. But will business-as-usual, as typically done in biotech, lead to maximum--or even reasonable--return on investment for shareholders? I think not. [/color]
[color=var(--text)]It all depends on the data. From the looks of it, they are lazar-focused on generating data through multiple trials. Like they should be. Keep the focus, lead with the data, quell any temptation for happy talk. There will be time to act on these potential scenarios as the data matures, because its the data that gives them leverage. Big Leverage! Because of that leverage I don't think Cytodyn is going to play by the normal business-as-usual rules. And what might that look like, praytell? Maybe some kind of holding company? Well, I like this early look at "horizontal licensing" and multi-indication development of leronlimab, with multiple licensees, and getting the drug to market expeditiously. Checks most of my boxes. (One of those would be some nice dividends coming our way).[/color]
8
